Fiche publication
Date publication
novembre 2025
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BESSIERES Igor
Tous les auteurs :
Pasquier C, Créhange G, Vendrely V, Bessières I, Quéro L, Huguet F, Modesto A
Lien Pubmed
Résumé
Oesophageal and gastric cancers are associated with a poor prognosis, as diagnosis is often delayed in fragile, comorbid patients. Radiotherapy plays a pivotal role in the treatment of oesophageal cancer. It is indicated in combination with chemotherapy for squamous cell carcinoma and for locally advanced, inoperable adenocarcinoma (i.e., non-operable patients or unresectable tumours). Additionally, chemoradiotherapy may be proposed in the preoperative setting for squamous cell carcinoma or for adenocarcinomas when peri-operative chemotherapy is not feasible. For resectable gastric adenocarcinomas, the indications for radiotherapy are limited. However, radiotherapy may be useful in a palliative setting in case of dysphagia or bleeding. Recent technological advances, such as image-guided radiotherapy and conformal intensity-modulated radiotherapy, have considerably improved the tolerance of treatments, particularly in curative approaches. These innovations optimize target volume coverage while limiting toxicity on adjacent organs at risk, notably the heart and lungs. We present here the updated guidelines of the Société française de radiothérapie oncologique (SFRO) regarding the indications and technical modalities of radiotherapy for oesophageal and gastric cancers.
Mots clés
Cancer de l’estomac, Cancer de l’œsophage, Cancer du cardia, Chemoradiotherapy, Chimioradiothérapie, Gastric cancer, Guidelines, Neoadjuvant, Néoadjuvant, Oesophageal cancer, Oesophagogastric junction cancer, Recommandations
Référence
Cancer Radiother. 2025 11 7;29(7-8):104759
